These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option. Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075 [Abstract] [Full Text] [Related]
5. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications. Ahmed A, Centor RM, Weaver MT, Perry GJ. Am Heart J; 2005 Apr; 149(4):737-43. PubMed ID: 15990761 [Abstract] [Full Text] [Related]
6. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. Ahmed A, Allman RM, DeLong JF, Bodner EV, Howard G. South Med J; 2002 Jul; 95(7):703-10. PubMed ID: 12144075 [Abstract] [Full Text] [Related]
7. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials. Saha SA, Molnar J, Arora RR. Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949 [Abstract] [Full Text] [Related]
8. Use of valsartan for the treatment of heart-failure patients not receiving ACE inhibitors: a budget impact analysis. Smith DG, Cerulli A, Frech FH. Clin Ther; 2005 Jun; 27(6):951-9. PubMed ID: 16117995 [Abstract] [Full Text] [Related]
12. The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. Klotz S, Danser AH, Foronjy RF, Oz MC, Wang J, Mancini D, D'Armiento J, Burkhoff D. J Am Coll Cardiol; 2007 Mar 20; 49(11):1166-74. PubMed ID: 17367660 [Abstract] [Full Text] [Related]
14. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Weir MR. Clin Ther; 2007 Sep 20; 29(9):1803-24. PubMed ID: 18035185 [Abstract] [Full Text] [Related]
15. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. Anand IS, Bishu K, Rector TS, Ishani A, Kuskowski MA, Cohn JN. Circulation; 2009 Oct 20; 120(16):1577-84. PubMed ID: 19805651 [Abstract] [Full Text] [Related]
17. Improving practice patterns in heart failure through a national cardiological network: the case of ACE-inhibitors. Porcu M, Opasich C, Scherillo M, Lucci D, De Maria R, Di Tano G, Maggioni AP, Italian Network on Congestive Heart Failure (IN-CHF) Investigators. Ital Heart J; 2002 Dec 20; 3(12):730-7. PubMed ID: 12611125 [Abstract] [Full Text] [Related]